Mr Casdagli has been an active investor in life sciences since joining MVM in 2002. Before joining MVM, he worked at PricewaterhouseCoopers where he qualified as a chartered accountant.
In February 2009, MVM acquired a 9.3% shareholding in Alliance Pharma. The relationship with MVM going forward will include the potential for MVM to lead equity fundraisings for any future product acquisitions undertaken by Alliance Pharma.
John Dawson, CEO of Alliance Pharma, said: “I am delighted to welcome Thomas to the board of Alliance Pharma and in particular look forward to working with him and with MVM on potential acquisitions. With his wide-ranging experience in life sciences and his strong business knowledge, Thomas brings an excellent mix of skills to the board.”